Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022830 | 0.97 | FAAH (0.54) | FAAHCA2TSHRTHRBCES1 | |
| SCHEMBL239450 | 0.92 | ALDH1A1 (0.44) | FAAHCA2NPC1S1PR2S1PR4 | |
| SCHEMBL3030767 | 0.85 | FAAH (0.48) | FAAHCA2TSHRTHRBCES1 | |
| SCHEMBL8679500 | 0.83 | FAAH (0.38) | FAAHCA2NPC1S1PR2S1PR4 | |
| SCHEMBL1679038 | 0.81 | FAAH (0.48) | FAAHCA2NPC1S1PR2S1PR4 | |
| SCHEMBL9491183 | 0.81 | CA2 (0.48) | FAAHCA2CES1 | |
| SCHEMBL243971 | 0.79 | FAAH (0.32) | FAAHCA2NPC1S1PR2S1PR4 | |
| SCHEMBL6152724 | 0.79 | FAAH (0.52) | FAAHCA2TSHRTHRBCES1 | |
| SCHEMBL3016235 | 0.79 | ALDH1A1 (0.39) | FAAHCA2NPC1S1PR2S1PR4 | |
| SCHEMBL7309994 | 0.79 | FAAH (0.46) | FAAHCA2NPC1S1PR2S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884017-B2 | 2-heteroarylcarboxylic acid amides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-11 | — | — | US | claimed |
| US-20140163067-A1 | Methods of Treatment of Limited Cognitive Impairment | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140155429-A1 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-06-05 | — | — | US | claimed |
| EP-2725906-A1 | METHODS OF TREATMENT OF LIMITED COGNITIVE IMPAIRMENT | Envivo Pharmaceuticals, Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-2706854-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH NICOTINE | Envivo Pharmaceuticals, Inc. (US) | 2014-03-19 | — | — | EP | claimed |
| EP-2640378-A1 | TREATMENT OF INFLAMMATION WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | Envivo Pharmaceuticals, Inc. (US) | 2013-09-25 | — | — | EP | claimed |
| US-20130231365-A1 | Treatment of Inflammation with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors | FORUM PHARMACEUTICALS, INC. | 2013-09-05 | — | — | US | claimed |
| WO-2013006365-A1 | METHODS OF TREATMENT OF LIMITED COGNITIVE IMPAIRMENT | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-01-10 | — | — | WO | claimed |
| WO-2012154710-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH NICOTINE | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-11-15 | — | — | WO | claimed |
| US-20120202842-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2012-08-09 | — | — | US | claimed |
| WO-2003055878-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2003-07-10 | — | — | WO | claimed |
| US-6492403-B1 | TREATING SYMPTOMS OF ACUTE OR CHRONIC DISORDER MEDIATED BY CLASSICAL PATHWAY OF COMPLEMENT CASCADE; PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | claimed |
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | claimed |
| EP-1152759-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-14 | — | — | EP | claimed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | claimed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | claimed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | claimed |
| WO-2000047194-A9 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | DIMENSIONAL PHARM INC (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |
| WO-2000047194-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163067-A1 | Methods of Treatment of Limited Cognitive Impairment | CHAT, SLC18A3, BCHE | FAAH 478/4885CA2 465/4885NPC1 139/4885 |
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | C1S, C1R, C9 | FAAH 1167/4885CA2 820/4885NPC1 630/4885 |
| US-20130231365-A1 | Treatment of Inflammation with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors | CHRNA7, CHRNA2, CHRNE | FAAH 333/4885CA2 1017/4885NPC1 2116/4885 |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | FAAH 1983/4885CA2 2597/4885NPC1 2579/4885 |
| US-20120202842-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | HCAR2, HCAR1, GRIN2A | FAAH 92/4885CA2 273/4885NPC1 104/4885 |
| US-20140155429-A1 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine | CHRNA7, CHRNA10, CHRNA5 | FAAH 1679/4885CA2 2360/4885NPC1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.